| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/14/2008 | CN100387623C Connexin transduction structural domain and bioactive protein of auxiliary protein, its production and use |
| 05/14/2008 | CN100387621C Production of antihuman antigen receptors and use thereof |
| 05/14/2008 | CN100387619C Regulatory/unfolding peptides of ezrin |
| 05/14/2008 | CN100387296C New dialysis method |
| 05/13/2008 | US7371872 (1R,4S,5S,6S)-4-(2'S-4'-methylthio-2'-aminobutanonyl)amino-2,2-dioxo-2 lambda 6-thia-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid; nervous system, psychological, and psychiatric disorders |
| 05/13/2008 | US7371846 Chemokine coreceptor fusion for use prevention and treatment of viral infection; immunotherapy |
| 05/13/2008 | US7371845 MAGE-A3 peptides presented by HLA class II molecules |
| 05/13/2008 | US7371844 Polypeptide of given sequence which binds to receptors; gene expression; use in treatment of osteoporosis, bone loss and raising cyclic AMP levels in cells |
| 05/13/2008 | US7371841 Identifying modulator of cold sensation and pain; drug screening; cancer diagnosis |
| 05/13/2008 | US7371836 PRO526 nucleic acids |
| 05/13/2008 | US7371834 Apoptosis-inducing factor |
| 05/13/2008 | US7371832 Polynucleotides encoding molecules associated with cell proliferation |
| 05/13/2008 | US7371828 Extracellular signal-regulated kinase sequences and methods of production and use |
| 05/13/2008 | US7371827 Antibodies against the PRO1126 polypeptide |
| 05/13/2008 | US7371826 Comprising human immunoglobulin g1 fc region, which mediates antibody-dependent cell-mediated cytotoxicity in presence of effector cells more effectively; binds fc gamma receptor iii with better affinity |
| 05/13/2008 | US7371824 PRO6093 polypeptides |
| 05/13/2008 | US7371823 Cyclic nucleotide-gated cation channel subunit 3B (CNG3B) polypeptides |
| 05/13/2008 | US7371822 Polypeptide of given sequence; use in prevention and treatment of cardiovascular, metabolic, inflammatory disorders; |
| 05/13/2008 | US7371821 Polypeptide of given sequence used as immunogen; cytokine adjuvant; |
| 05/13/2008 | US7371820 Nutraceuticals for the treatment, protection and restoration of connective tissues |
| 05/13/2008 | US7371819 Differs from nucleotide sequence of wild-type IFN alpha -17 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism[s]); anticarcinogenic and antiproliferative agents; side effect reduction |
| 05/13/2008 | US7371818 Comprises chordin-like polypeptide fo diagnosis, pre vention and treatment of bone and cancer disorders; gene therapy; antitumor agents |
| 05/13/2008 | US7371813 Method for use of IGF-binding protein for selective sensitization of target cells in vivo |
| 05/13/2008 | US7371812 Antiangiogenic peptides |
| 05/13/2008 | US7371811 Polypeptide of given sequence; diagnosis and treatment of bipolar disorders |
| 05/13/2008 | US7371810 Tachykinin peptides, precursor peptides thereof and genes encoding the same |
| 05/13/2008 | US7371809 Pharmacologically active antiviral peptides |
| 05/13/2008 | US7371735 Inhibitor oligonucleotides and their use for specific repression of a gene |
| 05/13/2008 | US7371734 Oligonucleotide compositions and their use for the modulation of immune responses |
| 05/13/2008 | US7371729 Boronic acid salts useful in parenteral formulations |
| 05/13/2008 | US7371728 Prostate peptide substrate: Gly-Hyp-Ala-Ser-Chg-Gln-Ser-Leu-Met-Lys(FITC)-Cys-NH2 where Hyp is hydroxyproline, Chg is cyclohexylglycine and FITC is Fluorescein isothiocyanate; near-infrared fluorescence probe |
| 05/13/2008 | US7371727 Methods and compositions for the treatment of gastrointestinal disorders |
| 05/13/2008 | US7371726 Neutralizing GDF8 epitope-based growth enhancing vaccine |
| 05/13/2008 | US7371725 Spondyloarthropathies |
| 05/13/2008 | US7371724 use in screening for compounds which interacts with Fc epsilon RI alpha; able to inhibit the IgE-induced mediator release without affecting the binding of IgE to the same receptor |
| 05/13/2008 | US7371723 Therapeutic agents comprising pro-apoptotic proteins |
| 05/13/2008 | US7371722 Pharmaceutical preparations and medicine capable of generating and/or containing thrombin |
| 05/13/2008 | US7371721 Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| 05/13/2008 | US7371720 Cationic peptides of the phylloseptin family isolated from the skin secretion of Phyllomedusa hypochondrialis |
| 05/13/2008 | US7371719 Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
| 05/13/2008 | US7371577 FLP-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
| 05/13/2008 | US7371572 A conjugated drug contains virus-like particle is joined to the antigen by a biotin molecule; bioassay; inhibiting HIV infection, viral infection |
| 05/13/2008 | US7371570 replication-competent; comprising an epstein-barr virus (EBV)-specific transcriptional regulatory element (TRE); genetic engineering |
| 05/13/2008 | US7371559 Polynucleotide of given sequence; treatment of chronic pain, migraine, asthma, urge incontinence, psoriasis, and cancer |
| 05/13/2008 | US7371543 Factor VII or VIIa-like molecules |
| 05/13/2008 | US7371539 Targeted polypeptide degradation |
| 05/13/2008 | US7371535 Detect binding with cells transfected with DNA |
| 05/13/2008 | US7371529 Methods and compositions for modulating gluconeogenesis using PGC-1 |
| 05/13/2008 | US7371411 oxidized glutathione-based compound having a stabilized disulfide bond |
| 05/13/2008 | US7371404 Amphoteric liposomes and their use |
| 05/13/2008 | US7371394 Antigenic composition of a Pseudomonas aeruginosa protein |
| 05/13/2008 | US7371393 Methods for reducing fecal shedding |
| 05/13/2008 | US7371392 Cd40 ligand adjuvant for respiratory syncytial virus |
| 05/13/2008 | US7371388 Treatment of Sjogren's syndrome by administration of TR18 polypeptides |
| 05/13/2008 | US7371386 Conserved motif of hepatitis C virus E2/NS1 region |
| 05/13/2008 | US7371385 Method of treating immune pathologies with low dose estrogen |
| 05/13/2008 | US7371379 Epidermal growth factors (ErbB2); gene expression inhibition; anticancer agents |
| 05/13/2008 | US7371377 Bone morpogenic proteins; endothelial growth factor e (vegfe); wound healing agents; tissue engineering; bradycardial agents |
| 05/13/2008 | US7371375 Protein |
| 05/13/2008 | US7371373 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta; free of human serum albumin; stability |
| 05/13/2008 | US7371372 Inosine monophosphate dehydrogenase inhibitor and interferon; hepatitis C |
| 05/13/2008 | US7371371 Interleukin-2 mutants with reduced toxicity |
| 05/13/2008 | US7371370 Using colony stimulating factor comprising amino acid sequence variation as therapeutic tools in treatment and prevention of hematopoietic, neurological or reproduction disorders |
| 05/13/2008 | US7371366 GlcNAc phosphotransferase of the lysosomal targeting pathway |
| 05/13/2008 | US7371364 Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy |
| 05/13/2008 | US7371257 Stent lining |
| 05/13/2008 | CA2438169C Modulated release particles for aerosol delivery |
| 05/13/2008 | CA2344222C Adhesive protein foam for surgical and/or therapeutic uses |
| 05/13/2008 | CA2315239C Nucleotide and protein sequence of mammastatin and methods of use |
| 05/13/2008 | CA2301717C Peptide with radio protective effect |
| 05/13/2008 | CA2234794C Novel antiproliferative protein from bacillus thuringiensis var. thuringiensis |
| 05/13/2008 | CA2206119C Irrigation solution and method for inhibition of pain, inflammation and spasm |
| 05/13/2008 | CA2184916C Use of fibroblast growth factors to stimulate bone growth |
| 05/13/2008 | CA2166291C Htlv-iinra compositions and assays for detecting htlv infection |
| 05/13/2008 | CA2125855C A stabilized pharmaceutical formulation comprising growth hormone and histidine |
| 05/13/2008 | CA1341573C Recombinant gamma interferons having enhanced stability and methods therefor |
| 05/08/2008 | WO2008055254A2 Formulations and methods for oral delivery of proteins |
| 05/08/2008 | WO2008055145A2 Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| 05/08/2008 | WO2008055112A2 Methods of treating autism and autism spectrum disorders |
| 05/08/2008 | WO2008055072A2 Compositions and methods for treating ocular diseases and conditions |
| 05/08/2008 | WO2008055059A2 Bi-functional peptides for multiple sclerosis treatment and diagnosis |
| 05/08/2008 | WO2008054792A2 Na+/k+-atpase-specific peptide inhibitors/activators of src and src family kinases |
| 05/08/2008 | WO2008054635A2 Proteins for use in diagnosing and treating infection and disease |
| 05/08/2008 | WO2008054540A2 Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| 05/08/2008 | WO2008054465A2 Method to reduce the risk and/or severity of anthrax infection |
| 05/08/2008 | WO2008054464A2 Broad spectrum immune and antiviral gene modulation by oral interferon |
| 05/08/2008 | WO2008054293A1 Composition, its use for treating systemic diseases a conditions, and product containing said composition |
| 05/08/2008 | WO2008054250A1 N'-{n-[3-oxo-lupen-28-oyl]-9-aminononanoyl}-3-amino-3-phenylpropeonic acid and the pharmaceutically acceptable derivatives thereof, a method for the production and the use thereof in the form of a medicinal agent |
| 05/08/2008 | WO2008054171A1 Omega conotoxins |
| 05/08/2008 | WO2008054098A1 Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy |
| 05/08/2008 | WO2008054057A1 A composition for preventing and treating acetaminophen inducing liver injury comprising the protein extracts from porphyra yezoensis |
| 05/08/2008 | WO2008053892A1 Pharmaceutical for promoting functional regeneration of damaged tissue |
| 05/08/2008 | WO2008053573A1 Remedy for malignant neoplasm |
| 05/08/2008 | WO2008053250A2 Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser |
| 05/08/2008 | WO2008053049A1 Modulators of cell adhesion molecules and use thereof |
| 05/08/2008 | WO2008053025A1 Therapeutic use of gba2 |
| 05/08/2008 | WO2008052338A1 Analysis of receptor biology using ligand coated beads |
| 05/08/2008 | WO2008052295A1 Process for the preparation of compounds of at1 receptor antagonists with angiotensin-(1-7), analogues thereof and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products |
| 05/08/2008 | WO2008034623A3 Medicament for the prophylaxis, treatment or diagnosis of ischaemic diseases |
| 05/08/2008 | WO2008034138A9 Methods and compositions for the topical oxygenation of hypoxic tissue |